Ophthalmological composition
US8207119B2 · kind B2 · utility
0Cited by
8References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2009 |
| Grant date | Jun 26, 2012 |
| Priority date | — |
| Expiry date | Mar 8, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.